These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 31467029)

  • 1. CDK5 Inhibitor Downregulates Mcl-1 and Sensitizes Pancreatic Cancer Cell Lines to Navitoclax.
    Kour S; Rana S; Contreras JI; King HM; Robb CM; Sonawane YA; Bendjennat M; Crawford AJ; Barger CJ; Kizhake S; Luo X; Hollingsworth MA; Natarajan A
    Mol Pharmacol; 2019 Oct; 96(4):419-429. PubMed ID: 31467029
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax).
    Leverson JD; Zhang H; Chen J; Tahir SK; Phillips DC; Xue J; Nimmer P; Jin S; Smith M; Xiao Y; Kovar P; Tanaka A; Bruncko M; Sheppard GS; Wang L; Gierke S; Kategaya L; Anderson DJ; Wong C; Eastham-Anderson J; Ludlam MJ; Sampath D; Fairbrother WJ; Wertz I; Rosenberg SH; Tse C; Elmore SW; Souers AJ
    Cell Death Dis; 2015 Jan; 6(1):e1590. PubMed ID: 25590800
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bcl-2/Bcl-xL inhibitor navitoclax increases the antitumor effect of Chk1 inhibitor prexasertib by inducing apoptosis in pancreatic cancer cells via inhibition of Bcl-xL but not Bcl-2.
    Morimoto Y; Takada K; Takeuchi O; Watanabe K; Hirohara M; Hamamoto T; Masuda Y
    Mol Cell Biochem; 2020 Sep; 472(1-2):187-198. PubMed ID: 32567031
    [TBL] [Abstract][Full Text] [Related]  

  • 4. JAK2V617F drives Mcl-1 expression and sensitizes hematologic cell lines to dual inhibition of JAK2 and Bcl-xL.
    Guo J; Roberts L; Chen Z; Merta PJ; Glaser KB; Shah OJ
    PLoS One; 2015; 10(3):e0114363. PubMed ID: 25781882
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bcl-xL inhibition by molecular-targeting drugs sensitizes human pancreatic cancer cells to TRAIL.
    Hari Y; Harashima N; Tajima Y; Harada M
    Oncotarget; 2015 Dec; 6(39):41902-15. PubMed ID: 26506422
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MCL-1 Is a Key Determinant of Breast Cancer Cell Survival: Validation of MCL-1 Dependency Utilizing a Highly Selective Small Molecule Inhibitor.
    Xiao Y; Nimmer P; Sheppard GS; Bruncko M; Hessler P; Lu X; Roberts-Rapp L; Pappano WN; Elmore SW; Souers AJ; Leverson JD; Phillips DC
    Mol Cancer Ther; 2015 Aug; 14(8):1837-47. PubMed ID: 26013319
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Navitoclax (ABT-263) accelerates apoptosis during drug-induced mitotic arrest by antagonizing Bcl-xL.
    Shi J; Zhou Y; Huang HC; Mitchison TJ
    Cancer Res; 2011 Jul; 71(13):4518-26. PubMed ID: 21546570
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dinaciclib, a Cyclin-Dependent Kinase Inhibitor Promotes Proteasomal Degradation of Mcl-1 and Enhances ABT-737-Mediated Cell Death in Malignant Human Glioma Cell Lines.
    Jane EP; Premkumar DR; Cavaleri JM; Sutera PA; Rajasekar T; Pollack IF
    J Pharmacol Exp Ther; 2016 Feb; 356(2):354-65. PubMed ID: 26585571
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis of aminopyrazole analogs and their evaluation as CDK inhibitors for cancer therapy.
    Rana S; Sonawane YA; Taylor MA; Kizhake S; Zahid M; Natarajan A
    Bioorg Med Chem Lett; 2018 Dec; 28(23-24):3736-3740. PubMed ID: 30343954
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel small-molecule IAP antagonist, AZD5582, draws Mcl-1 down-regulation for induction of apoptosis through targeting of cIAP1 and XIAP in human pancreatic cancer.
    Moon JH; Shin JS; Hong SW; Jung SA; Hwang IY; Kim JH; Choi EK; Ha SH; Kim JS; Kim KM; Hong DW; Kim D; Kim YS; Kim JE; Kim KP; Hong YS; Choi EK; Lee JS; Hattersley M; Jin DH; Kim TW
    Oncotarget; 2015 Sep; 6(29):26895-908. PubMed ID: 26314849
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Loss in MCL-1 function sensitizes non-Hodgkin's lymphoma cell lines to the BCL-2-selective inhibitor venetoclax (ABT-199).
    Phillips DC; Xiao Y; Lam LT; Litvinovich E; Roberts-Rapp L; Souers AJ; Leverson JD
    Blood Cancer J; 2015 Nov; 5(11):e368. PubMed ID: 26565405
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PI3K/mTOR dual inhibitor NVP-BEZ235 decreases Mcl-1 expression and sensitizes ovarian carcinoma cells to Bcl-xL-targeting strategies, provided that Bim expression is induced.
    Jebahi A; Villedieu M; Pétigny-Lechartier C; Brotin E; Louis MH; Abeilard E; Giffard F; Guercio M; Briand M; Gauduchon P; Lheureux S; Poulain L
    Cancer Lett; 2014 Jun; 348(1-2):38-49. PubMed ID: 24650799
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting the differential addiction to anti-apoptotic BCL-2 family for cancer therapy.
    Inoue-Yamauchi A; Jeng PS; Kim K; Chen HC; Han S; Ganesan YT; Ishizawa K; Jebiwott S; Dong Y; Pietanza MC; Hellmann MD; Kris MG; Hsieh JJ; Cheng EH
    Nat Commun; 2017 Jul; 8():16078. PubMed ID: 28714472
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aspirin overcomes Navitoclax-resistance in hepatocellular carcinoma cells through suppression of Mcl-1.
    Li G; Zhang S; Fang H; Yan B; Zhao Y; Feng L; Ma X; Ye X
    Biochem Biophys Res Commun; 2013 May; 434(4):809-14. PubMed ID: 23611778
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ionizing radiation sensitizes breast cancer cells to Bcl-2 inhibitor, ABT-737, through regulating Mcl-1.
    Wu H; Schiff DS; Lin Y; Neboori HJ; Goyal S; Feng Z; Haffty BG
    Radiat Res; 2014 Dec; 182(6):618-25. PubMed ID: 25409124
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bcl-xl and Mcl-1 are the major determinants of the apoptotic response to dual PI3K and MEK blockage.
    Jokinen E; Koivunen JP
    Int J Oncol; 2015 Sep; 47(3):1103-10. PubMed ID: 26135106
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cyclin E/Cdk2-dependent phosphorylation of Mcl-1 determines its stability and cellular sensitivity to BH3 mimetics.
    Choudhary GS; Tat TT; Misra S; Hill BT; Smith MR; Almasan A; Mazumder S
    Oncotarget; 2015 Jul; 6(19):16912-25. PubMed ID: 26219338
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation.
    Chen S; Dai Y; Harada H; Dent P; Grant S
    Cancer Res; 2007 Jan; 67(2):782-91. PubMed ID: 17234790
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BCL-XL and MCL-1 are the key BCL-2 family proteins in melanoma cell survival.
    Lee EF; Harris TJ; Tran S; Evangelista M; Arulananda S; John T; Ramnac C; Hobbs C; Zhu H; Gunasingh G; Segal D; Behren A; Cebon J; Dobrovic A; Mariadason JM; Strasser A; Rohrbeck L; Haass NK; Herold MJ; Fairlie WD
    Cell Death Dis; 2019 Apr; 10(5):342. PubMed ID: 31019203
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aminopyrazole based CDK9 PROTAC sensitizes pancreatic cancer cells to venetoclax.
    King HM; Rana S; Kubica SP; Mallareddy JR; Kizhake S; Ezell EL; Zahid M; Naldrett MJ; Alvarez S; Law HC; Woods NT; Natarajan A
    Bioorg Med Chem Lett; 2021 Jul; 43():128061. PubMed ID: 33895280
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.